Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DAPTACEL as a 5th Dose in Children 4-6 Years
NCT00258895Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2005
- Primary completion
- Dec 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of acellular pertussis vaccine in diphtheria, Tetanus and pertussis (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of Participants Reporting Solicited Local or Systemic Reactions Post-Dose 5, Percentage of Participants With Anti-Pertussis 4-Fold Rises Post-Dose 5 and 3 more. Started Mar 2005; status: completed.
02
Drugs
acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT00258895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258895.